Clinical trials: Breast Cancer
Breast Cancer
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
This was a randomized, double-blind, placebo-controlled study conducted in Chinese women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, plus an open-label…
- Trial name
- NCT03671330
- Testing
- Ribociclib, NSAI: Letrozole or Anastrazole, Goserelin
- Where
- 24 sites in China
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasm, Pain
Effectiveness of a Modern Educational Intervention in Breast Cancer Patients
In addition to fatigue, pain is the most frequent and persistent symptom following breast cancer and breast cancer treatment. Despite the effectiveness of different physical therapy modalities, such as manual techniques, passive…
- Trial name
- EduCan (NCT03351075)
- Testing
- Standard physical therapy program, Modern educational program, Traditional biomedical educational program
- Where
- Belgium
- Volunteers
- 184 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy…
- Trial name
- NCT06086340
- Testing
- Palbociclib, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 779 people
- Sponsor
- Pfizer
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at…
- Trial name
- SOLO3 (NCT02282020)
- Testing
- OLAPARIB, Single agent chemotherapy
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
Lung Cancer, Esophageal Cancer
Mithramycin for Lung, Esophagus, and Other Chest Cancers
Background: Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment.
- Conditions
- Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Neoplasms
- Trial name
- NCT01624090
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening
This study is looking at a breast cancer screening technique, restriction spectrum imaging (RSI), as a possible alternative to the breast Magnetic Resonance Imaging (MRI) used by most healthcare professionals.
- Trial name
- NCT03495115
- Testing
- MRI, RSI
- Where
- United States
- Volunteers
- 460 people
- Sponsor
- Beth Israel Deaconess Medical Center
Breast Cancer
Ear Acupuncture During Chemotherapy Infusion for Breast Cancer, a Feasibility Study
This research study is evaluating ear acupuncture as a possible treatment to reduce symptoms related to receiving chemotherapy.
- Trial name
- NCT03170648
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Peripheral Neuropathy, Stage 0 Breast Cancer
Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer
This pilot clinical trial studies how well ultrasound works in detecting taxane-induced neuropathy in patients with breast cancer.
- Conditions
- Peripheral Neuropathy, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer
- Trial name
- NCT03139435
- Testing
- Biopsy, Questionnaire Administration, Ultrasound Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Triple Negative Breast Cancer
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths in American women. Metastatic disease including metastatic breast cancer unfortunately remains incurable.
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT01307891
- Testing
- Abraxane alone, Abraxane + Tigatuzumab
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of Alabama at Birmingham
Metastatic Breast Cancer
Telephone Support for Metastatic Breast Cancer Patients
This trial tests telephone-based Acceptance and Commitment Therapy (ACT), a type of psychotherapy, to reduce fatigue interference with activities, mood, and cognition in metastatic breast cancer (MBC) cancer patients.
- Trial name
- NCT03998618
- Testing
- Acceptance and Commitment Therapy, Education/Support
- Where
- 3 sites in United States
- Volunteers
- 250 people
- Sponsor
- Indiana University
Advanced Triple Negative Breast Cancer
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
This is a phase 1b/2 open-label study to evaluate the safety and efficacy of sacituzumab govitecan-hziy in combination with chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK) in subjects with Triple Negative Breast…
- Trial name
- NCT04927884
- Testing
- N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- ImmunityBio, Inc.
Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal symptoms in women receiving hormone therapy for breast cancer.
- Conditions
- Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer
- Trial name
- NCT01194440
- Testing
- letrozole, zoledronic acid
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Triple Negative Breast Cancer
A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
This is a Phase II study designed to assess efficacy and safety of talazoparib, high dose radiation, and atezolizumab in patients with metastatic TNBC that is PD-L1 positive.
- Trial name
- TARA (NCT04690855)
- Testing
- Talazoparib, Atezolizumab, Radiation
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Mylin A. Torres, MD
Breast Cancer
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
This randomized study will compare maintenance therapy with Avastin (bevacizumab) + Xeloda (capecitabine) versus Avastin alone, in patients with HER2-negative metastatic breast cancer who have not progressed during first-line…
- Trial name
- NCT00929240
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda]
- Where
- 63 sites in Brazil, China and 9 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen
This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.
- Trial name
- NCT00038103
- Testing
- Exemestane, Celecoxib + Exemestane
- Where
- 20 sites in United States, Belgium and 7 more
- Volunteers
- 111 people
- Sponsor
- Pfizer
Breast Cancer, Early Detection of Cancer
A Prospective Study to Evaluate Clinical Performance of Thermalytix in Detecting Breast Cancers
The purpose of this study is to determine the clinical performance of AI-based Thermalytix with the current standard-of-care diagnostic modalities in women.
- Trial name
- NCT04688086
- Testing
- Thermalytix
- Where
- India
- Volunteers
- 687 people, healthy volunteers welcome
- Sponsor
- Niramai Health Analytix Private Limited
Breast Cancer
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be effective in preventing breast cancer.
- Trial name
- NCT00088972
- Testing
- celecoxib
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00054275
- Testing
- docetaxel, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Paula Silverman, MD
ER+ Breast Cancer
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
The addition of entinostat to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor.
- Trial name
- NCT00828854
- Testing
- Entinostat, Aromatase Inhibitor (AI) Therapy
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Syndax Pharmaceuticals
Stage IV (Metastatic) Breast Cancer
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
The purpose of this study is to: 1) determine the optimal tolerated dose of ABI-007 and vinorelbine, given concurrently on a weekly basis, in the absence of planned growth factor support with granulocyte colony-stimulating factor…
- Trial name
- NCT00140140
- Testing
- ABI-007, vinorelbine, Trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.